Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pause or continue? study tests ACE inhibitor timing to prevent kidney damage

NCT ID NCT07184918

Knowledge-focused Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether continuing or temporarily stopping the blood pressure medicine Ramipril (an ACE inhibitor) before coronary angiography affects the risk of kidney injury from the contrast dye. 44 adults were randomly assigned to either keep taking their usual dose or stop it 48 hours before and restart 72 hours after the procedure. Researchers measured kidney function and injury markers to see which approach is safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ramipril (an ACE inhibitor)
What this could lead to
If it works, this could help doctors decide whether to pause ACE inhibitors before angiography to protect kidneys.
What could go wrong
This is a small, completed study with only 44 people, so results may not apply to everyone. It does not test a new treatment, just compares two approaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Feb 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) scheduled for elective coronary angiography * Currently on ACE inhibitor (Ramipril) * Serum creatinine ≤1.5 mg/dL Exclusion Criteria: * STEMI within last 2 weeks * NYHA Class IV heart failure * CrCl \<50 mL/min * Serum potassium \>5.0 mEq/L * Recent contrast exposure * Pregnancy or breastfeeding * Cardiogenic shock or sepsis * Severe uncontrolled hypertension

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Contrast-induced nephropathy Coronary angiography

Contacts and locations

Locations

  • Faculty of Pharmacy Tanta university

    Tanta, Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.